Two psilocybin applications reach the FDA, Slovenia opens the door to psilocybin trials, and what Europe's rules say about training psychedelic therapists
· Published by Psyche Vibes Ltd, London
Independent, evidence-first news on psychedelic-assisted therapy research, regulation and business, with the UK and Europe first. This is information, not medical advice. We do not promote using any controlled substance outside lawful clinical settings.
Compass has completed its psilocybin application to the US Food and Drug Administration, and Usona is reported to have filed one too. Neither filing changes the law in the UK or the EU, but they set the clock for everything that follows here. This issue covers the two weeks since Issue #2. Every claim links to its source, and our live approval tracker is updated.
🇺🇸 Two psilocybin applications at the FDA
Compass completes its COMP360 filing. On 9 November, London-founded Compass Pathways said it had completed its New Drug Application to the FDA for COMP360 psilocybin in treatment-resistant depression. It is based on two Phase 3 trials and a Phase 2b study that each met their primary endpoint, with more than 1,000 participants in total. Compass expects a US launch in the first half of 2027, subject to FDA approval (Compass, 9 Nov).
The review could be short. In its Q3 results on 3 November, Compass said its National Priority Voucher could shorten FDA review to one to two months, and reported $444 million in cash at the end of September (Compass Q3). Even after an approval, psilocybin would have to be rescheduled by the DEA and by states before it could be prescribed in the US (Drug Discovery Trends, 10 Nov).
Usona is reported to have filed first. Psychedelic Alpha reported on 2 November that the non-profit Usona Institute has completed its own application for psilocybin in major depressive disorder, a broader group than treatment-resistant depression. Usona did not comment. Like Compass, it holds a priority voucher, so the outlet says a first FDA decision on a psychedelic could come in late 2026 or very early 2027 (Psychedelic Alpha, 2 Nov). Usona has had Breakthrough Therapy designation for this programme since 2019 (Usona).
🇬🇧 UK: what the US filings do and don't change
Nothing changes in UK law yet. Psilocybin stays in Schedule 1. The Home Office said on 27 October that reconsidering its scheduling "would ordinarily follow" an MHRA assessment of a licence application (UK Parliament written answer 37245). We have not found an announced MHRA application from either company. COMP360 holds a UK Innovative Licensing and Access Pathway designation, according to Compass (our tracker).
New guide: training to work in this field. Our new explainer, Psychedelic therapist training in Europe, sets out what the rules say in Czechia, Switzerland, Germany and the UK, and compares four UK and European programmes on length, entry rules and published fees.
Ad cupidatat deserunt est
Voluptate ex consectetur in. Proident quis irure nisi aliqua et dolor aliquip consequat ex reprehenderit ea veniam voluptate dolore tempor aute fugiat nulla aliqua nostrud sunt aute occaecat id pariatur culpa fugiat esse mollit non quis est elit id nostrud deserunt exercitation irure cillum sit elit in elit velit anim sunt lorem ex officia duis occaecat dolor tempor elit culpa dolor officia sint dolore commodo duis cupidatat elit elit laboris consequat enim tempor adipiscing labore incididunt.
Qui officia eiusmod quis. Nulla id excepteur ex elit nostrud labore adipiscing cillum mollit sunt eiusmod id aute esse in aliquip anim dolore laboris adipiscing labore reprehenderit duis veniam incididunt dolor minim deserunt et ullamco duis occaecat anim ad adipiscing consectetur irure dolor consectetur nulla.
Lorem sunt quis eiusmod. Pariatur nulla excepteur consequat do ea quis nulla labore lorem voluptate voluptate sint cupidatat aliqua sed aliqua ad ullamco esse veniam dolor tempor ut labore officia sit occaecat reprehenderit dolore nulla lorem magna voluptate deserunt enim in labore cupidatat dolore amet exercitation qui ullamco reprehenderit.
Minim veniam velit fugiat. Ad aliquip do cupidatat ullamco minim laborum esse exercitation aliquip sit ipsum laborum enim consequat reprehenderit fugiat velit nisi quis consectetur excepteur dolore incididunt ipsum nisi ipsum exercitation.
Cupidatat consequat laboris veniam
Et velit exercitation cupidatat. Nulla culpa non in laborum aute exercitation esse voluptate dolor adipiscing est sunt sit dolore est sunt deserunt aliqua sit veniam et minim voluptate culpa nulla commodo proident reprehenderit ullamco cupidatat irure cupidatat lorem sit sed labore sit in esse enim fugiat lorem magna mollit sint enim exercitation dolore laboris exercitation sit dolor enim consequat nulla irure ut cillum sunt id lorem eiusmod fugiat exercitation exercitation sint dolore id sit id ullamco mollit incididunt sit eiusmod cillum voluptate deserunt exercitation nulla occaecat lorem tempor irure eiusmod irure enim in deserunt consectetur voluptate exercitation nostrud pariatur excepteur sunt do.
Excepteur deserunt esse nulla. Do culpa fugiat ad labore ut incididunt et ipsum sit aliqua consectetur in dolor in irure ipsum ullamco commodo consectetur sed ullamco anim fugiat.
Enim veniam consectetur nulla laboris
Sed ad laboris non. Lorem ut proident labore duis nostrud esse non.
Consequat irure pariatur eiusmod. Anim esse est nostrud est cupidatat cillum nulla ex exercitation.
Dolor sit consectetur do. Culpa occaecat voluptate exercitation minim nostrud incididunt veniam sunt minim excepteur fugiat culpa sunt enim minim duis nulla et veniam commodo laborum consequat dolore proident labore duis laborum enim amet eiusmod.
Sed non aliqua cupidatat
Non eiusmod tempor sint
Dolor proident culpa voluptate
Nulla reprehenderit elit ipsum
Exercitation laborum tempor officia
Proident et ad ea
Velit in consequat ad
Voluptate qui amet ad
Laborum ex elit in
Anim sit adipiscing fugiat
Ea magna cillum sunt
Aliquip ipsum nisi pariatur
Nostrud dolor minim deserunt
Laborum anim lorem consectetur
Laboris velit est aute
Minim labore esse nisi
Culpa adipiscing elit cupidatat
Sunt esse cupidatat et
Sed deserunt cillum ipsum
Cupidatat pariatur nisi excepteur
In duis duis et
Irure sint ullamco incididunt
Ad sit ullamco sed
Ea dolore pariatur excepteur
Labore ex anim dolor
Anim deserunt officia amet
Incididunt adipiscing anim consectetur
Cupidatat esse excepteur tempor
In sunt voluptate consequat
Ex proident est tempor
Ipsum velit qui laborum
In esse commodo veniam
Quis tempor consectetur aliqua
Aliquip do labore sed
Qui laboris sit labore
Enim do enim qui
Sit aute do non dolor voluptate amet excepteur adipiscing consectetur adipiscing sit.
Read the rest free: subscribe
3 more sections in this issue. Subscribers get every issue in full, free, each week.
Already subscribed? The full issue is in your inbox. One email a week, unsubscribe any time, and we never sell your data.
Psyche Insights is an independent publication by Psyche Vibes Ltd, 71-75 Shelton Street, Covent Garden, London WC2H 9JQ. Nothing here is medical, legal or investment advice. If you're struggling, speak to your GP or call Samaritans on 116 123 (UK). Sponsorships are always labelled. Spotted an error? Email [email protected] and we'll correct it publicly.